Tsuchimoto Kim R sold $290K of MNPR
Tsuchimoto Kim R sold 4,090 shares of Monopar Therapeutics (MNPR) at an average of $70.92 ($70.10–$72.21, $0.29M total) across 4 trades over 2026-11-02 to 2026-11-04 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The director's exit reduces insider ownership to zero, potentially affecting investor perception and short‑term price action.
Market read
Primary insider sale filing; modest size but may trigger short‑term sell pressure.
What to watch
The 10b5‑1 plan pre‑arranges sales, which may mitigate negative perception; also, the sale size is modest relative to market cap.
Background
SEC Form 4 filing discloses insider transactions; this is the first public report of the director's sale.
Ticker impact
Director Tsuchimoto Kim R sold 4,090 shares for $290K via a 10b5‑1 plan, reducing holdings to zero.
likely downward pressure as the market prices in the insider sell
Form 4 is a primary source; a director exiting with a sizable block often triggers short‑term sell‑off.
Market effects
Minimal; biotech sector may view the sale as a company‑specific signal rather than a broader trend.
None; the filing is U.S.‑focused.
Low; no macro or global implications.
Counterpoint
The sale could be a routine liquidity event unrelated to fundamentals, so the stock may remain stable.
Key entities
- CompanyMonopar Therapeutics
Biotech firm listed on NASDAQ under ticker MNPR.
- IndividualTsuchimoto Kim R
Director of Monopar Therapeutics who executed the sale.
